Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Swedish Orphan Biovitrum price target raised to SEK 160 from SEK 155 at Barclays » 11:19
07/23/21
07/23
11:19
07/23/21
11:19
BIOVF

Swedish Orphan Biovitrum

$20.00 /

+0.605 (+3.12%)

Barclays analyst Rosie…

Barclays analyst Rosie Turner raised the firm's price target on Swedish Orphan Biovitrum to SEK 160 from SEK 155 and keeps an Equal Weight rating on the shares.

ShowHide Related Items >><<
BIOVF Swedish Orphan Biovitrum
$20.00 /

+0.605 (+3.12%)

BIOVF Swedish Orphan Biovitrum
$20.00 /

+0.605 (+3.12%)

07/22/21 Pareto
Swedish Orphan Biovitrum upgraded to Buy from Hold at Pareto
07/21/21 Deutsche Bank
Swedish Orphan Biovitrum upgraded to Buy from Hold at Deutsche Bank
05/05/21 DNB Markets
Swedish Orphan Biovitrum downgraded to Hold from Buy at DNB Markets
05/05/21 SEB Equities
Swedish Orphan Biovitrum downgraded to Hold from Buy at SEB Equities
Upgrade
Swedish Orphan Biovitrum upgraded to Buy from Hold at Pareto » 05:05
07/22/21
07/22
05:05
07/22/21
05:05
BIOVF

Swedish Orphan Biovitrum

$19.40 /

+0.4195 (+2.21%)

Pareto analyst Peter…

Pareto analyst Peter Ostling upgraded Swedish Orphan Biovitrum to Buy from Hold with a SEK 195 price target.

ShowHide Related Items >><<
BIOVF Swedish Orphan Biovitrum
$19.40 /

+0.4195 (+2.21%)

BIOVF Swedish Orphan Biovitrum
$19.40 /

+0.4195 (+2.21%)

07/21/21 Deutsche Bank
Swedish Orphan Biovitrum upgraded to Buy from Hold at Deutsche Bank
05/05/21 DNB Markets
Swedish Orphan Biovitrum downgraded to Hold from Buy at DNB Markets
05/05/21 SEB Equities
Swedish Orphan Biovitrum downgraded to Hold from Buy at SEB Equities
04/20/21 Deutsche Bank
Swedish Orphan Biovitrum initiated with a Hold at Deutsche Bank
Upgrade
Swedish Orphan Biovitrum upgraded to Buy from Hold at Deutsche Bank » 19:33
07/21/21
07/21
19:33
07/21/21
19:33
BIOVF

Swedish Orphan Biovitrum

$19.40 /

+0.4195 (+2.21%)

Deutsche Bank analyst…

Deutsche Bank analyst Emmanuel Papadakis upgraded Swedish Orphan Biovitrum to Buy from Hold with a SEK 200 price target. The analyst says the company's Q2 results confirmed stabilization and "some things to look forward to."

ShowHide Related Items >><<
BIOVF Swedish Orphan Biovitrum
$19.40 /

+0.4195 (+2.21%)

BIOVF Swedish Orphan Biovitrum
$19.40 /

+0.4195 (+2.21%)

05/05/21 DNB Markets
Swedish Orphan Biovitrum downgraded to Hold from Buy at DNB Markets
05/05/21 SEB Equities
Swedish Orphan Biovitrum downgraded to Hold from Buy at SEB Equities
04/20/21 Deutsche Bank
Swedish Orphan Biovitrum initiated with a Hold at Deutsche Bank
02/24/21 Barclays
Swedish Orphan Biovitrum downgraded to Equal Weight from Overweight at Barclays
Over a month ago
Hot Stocks
Apellis, Swedish Orphan Biovitrum report results from Phase 3 Prince study » 07:05
05/25/21
05/25
07:05
05/25/21
07:05
APLS

Apellis

$47.25 /

-0.74 (-1.54%)

, BIOVF

Swedish Orphan Biovitrum

$17.85 /

-0.01 (-0.06%)

Apellis Pharmaceuticals…

Apellis Pharmaceuticals (APLS) and Swedish Orphan Biovitrum (BIOVF) reported positive top-line results from the Phase 3 PRINCE study evaluating the efficacy and safety of EMPAVELI in adults with paroxysmal nocturnal hemoglobinuria who are treatment naive, meaning they had not received a complement inhibitor within three months before entering the study. EMPAVELI demonstrated statistical superiority on the co-primary endpoints of hemoglobin stabilization and reduction in lactate dehydrogenase compared to standard of care, which did not include complement inhibitors, at Week 26. 86% of EMPAVELI-treated patients achieved hemoglobin stabilization compared to 0% of patients on standard of care. Hemoglobin stabilization was defined as an avoidance of a greater than1 g/dL decrease in hemoglobin levels in the absence of transfusions. Mean LDH in the EMPAVELI group decreased by 90% from a baseline of 2151 U/L to 211 U/L, which is within the normal range, compared to a 14% reduction on standard of care from a baseline of 1946 U/L to 1681 U/L.EMPAVELI also achieved statistical superiority on several secondary endpoints, including improvements in hemoglobin levels and transfusion avoidance, compared to standard of care, which did not include complement inhibitors. Mean hemoglobin levels in the EMPAVELI group increased from 9.4 g/dL to 12.1 g/dL compared to an increase from a baseline of 8.7 g/dL to 9.4 g/dL on standard of care. 91% of patients on EMPAVELI were transfusion free compared to 22% on standard of care. The safety profile of EMPAVELI was consistent with previous studies. At Week 26, 9% of patients in the EMPAVELI group experienced a serious adverse event compared to 17% on standard of care. One death was reported in each group, and neither were related to treatment. No cases of meningitis or thrombosis were reported in either group. The most common adverse events reported during the study in the EMPAVELI and standard of care groups, respectively, were injection site reaction, hypokalemia, and fever.

ShowHide Related Items >><<
BIOVF Swedish Orphan Biovitrum
$17.85 /

-0.01 (-0.06%)

APLS Apellis
$47.25 /

-0.74 (-1.54%)

APLS Apellis
$47.25 /

-0.74 (-1.54%)

05/20/21 UBS
Apellis initiated with a Buy at UBS
05/18/21 BMO Capital
Apellis price target raised to $68 from $64 at BMO Capital
05/17/21 Oppenheimer
Apellis price target raised to $67 from $64 at Oppenheimer
05/17/21 Raymond James
Apellis price target raised to $115 from $104 at Raymond James
BIOVF Swedish Orphan Biovitrum
$17.85 /

-0.01 (-0.06%)

05/05/21 DNB Markets
Swedish Orphan Biovitrum downgraded to Hold from Buy at DNB Markets
05/05/21 SEB Equities
Swedish Orphan Biovitrum downgraded to Hold from Buy at SEB Equities
04/20/21 Deutsche Bank
Swedish Orphan Biovitrum initiated with a Hold at Deutsche Bank
02/24/21 Barclays
Swedish Orphan Biovitrum downgraded to Equal Weight from Overweight at Barclays
APLS Apellis
$47.25 /

-0.74 (-1.54%)

APLS Apellis
$47.25 /

-0.74 (-1.54%)

APLS Apellis
$47.25 /

-0.74 (-1.54%)

Downgrade
Swedish Orphan Biovitrum downgraded to Hold from Buy at DNB Markets » 05:14
05/05/21
05/05
05:14
05/05/21
05:14
BIOVF

Swedish Orphan Biovitrum

$17.30 /

+ (+0.00%)

DNB Markets analyst David…

DNB Markets analyst David Martinsson downgraded Swedish Orphan Biovitrum to Hold from Buy with a SEK 151 price target.

ShowHide Related Items >><<
BIOVF Swedish Orphan Biovitrum
$17.30 /

+ (+0.00%)

BIOVF Swedish Orphan Biovitrum
$17.30 /

+ (+0.00%)

05/05/21 SEB Equities
Swedish Orphan Biovitrum downgraded to Hold from Buy at SEB Equities
04/20/21 Deutsche Bank
Swedish Orphan Biovitrum initiated with a Hold at Deutsche Bank
02/24/21 Barclays
Swedish Orphan Biovitrum downgraded to Equal Weight from Overweight at Barclays
02/19/21 Danske Bank
Swedish Orphan Biovitrum downgraded to Hold from Buy at Danske Bank
Downgrade
Swedish Orphan Biovitrum downgraded to Hold from Buy at SEB Equities » 05:13
05/05/21
05/05
05:13
05/05/21
05:13
BIOVF

Swedish Orphan Biovitrum

$17.30 /

+ (+0.00%)

SEB Equities analyst…

SEB Equities analyst Christopher Uhde downgraded Swedish Orphan Biovitrum to Hold from Buy.

ShowHide Related Items >><<
BIOVF Swedish Orphan Biovitrum
$17.30 /

+ (+0.00%)

BIOVF Swedish Orphan Biovitrum
$17.30 /

+ (+0.00%)

04/20/21 Deutsche Bank
Swedish Orphan Biovitrum initiated with a Hold at Deutsche Bank
02/24/21 Barclays
Swedish Orphan Biovitrum downgraded to Equal Weight from Overweight at Barclays
02/19/21 Danske Bank
Swedish Orphan Biovitrum downgraded to Hold from Buy at Danske Bank
07/22/20 Barclays
Swedish Orphan Biovitrum upgraded to Overweight from Equal Weight at Barclays
Over a quarter ago
Initiation
Swedish Orphan Biovitrum initiated with a Hold at Deutsche Bank » 06:08
04/20/21
04/20
06:08
04/20/21
06:08
BIOVF

Swedish Orphan Biovitrum

$16.87 /

+0.065 (+0.39%)

Deutsche Bank analyst…

Deutsche Bank analyst Emmanuel Papadakis initiated coverage of Swedish Orphan Biovitrum with a Hold rating and SEK 130 price target. The analyst says the company's debt to EBITDA metrics "are still not obviously enticing."

ShowHide Related Items >><<
BIOVF Swedish Orphan Biovitrum
$16.87 /

+0.065 (+0.39%)

BIOVF Swedish Orphan Biovitrum
$16.87 /

+0.065 (+0.39%)

02/24/21 Barclays
Swedish Orphan Biovitrum downgraded to Equal Weight from Overweight at Barclays
02/19/21 Danske Bank
Swedish Orphan Biovitrum downgraded to Hold from Buy at Danske Bank
07/22/20 Barclays
Swedish Orphan Biovitrum upgraded to Overweight from Equal Weight at Barclays
06/19/20 Barclays
Barclays upgrades Swedish Orphan to Equal Weight on favorable trends
Conference/Events
Swedish Orphan Biovitrum participates in a conference call with Jefferies » 09:23
03/05/21
03/05
09:23
03/05/21
09:23
BIOVF

Swedish Orphan Biovitrum

$0.00 /

+ (+0.00%)

Healthcare Analyst Yang…

Healthcare Analyst Yang holds a conference call on March 5 at 10 am hosted by Jefferies.

ShowHide Related Items >><<
BIOVF Swedish Orphan Biovitrum
$0.00 /

+ (+0.00%)

BIOVF Swedish Orphan Biovitrum
$0.00 /

+ (+0.00%)

02/24/21 Barclays
Swedish Orphan Biovitrum downgraded to Equal Weight from Overweight at Barclays
02/19/21 Danske Bank
Swedish Orphan Biovitrum downgraded to Hold from Buy at Danske Bank
07/22/20 Barclays
Swedish Orphan Biovitrum upgraded to Overweight from Equal Weight at Barclays
06/19/20 Barclays
Barclays upgrades Swedish Orphan to Equal Weight on favorable trends
Downgrade
Swedish Orphan Biovitrum downgraded to Equal Weight from Overweight at Barclays » 06:38
02/24/21
02/24
06:38
02/24/21
06:38
BIOVF

Swedish Orphan Biovitrum

$0.00 /

+ (+0.00%)

Barclays analyst Rosie…

Barclays analyst Rosie Turner downgraded Swedish Orphan Biovitrum to Equal Weight from Overweight with a price target of SEK 150, down from SEK 185. Increasing competitive pressure for the core haematology franchise, combined with COVID-related headwinds for parts of the immunology business signals the continuation of Biovitrum's earnings downgrade cycle, Turner tells investors in a research note.

ShowHide Related Items >><<
BIOVF Swedish Orphan Biovitrum
$0.00 /

+ (+0.00%)

BIOVF Swedish Orphan Biovitrum
$0.00 /

+ (+0.00%)

02/19/21 Danske Bank
Swedish Orphan Biovitrum downgraded to Hold from Buy at Danske Bank
07/22/20 Barclays
Swedish Orphan Biovitrum upgraded to Overweight from Equal Weight at Barclays
06/19/20 Barclays
Barclays upgrades Swedish Orphan to Equal Weight on favorable trends
06/19/20 Barclays
Swedish Orphan upgraded to Equal Weight from Underweight at Barclays
Downgrade
Swedish Orphan Biovitrum downgraded to Hold from Buy at Danske Bank » 05:20
02/19/21
02/19
05:20
02/19/21
05:20
BIOVF

Swedish Orphan Biovitrum

$0.00 /

+ (+0.00%)

Danske Bank analyst…

Danske Bank analyst Daniel Albin downgraded Swedish Orphan Biovitrum to Hold from Buy with a SEK 164 price target.

ShowHide Related Items >><<
BIOVF Swedish Orphan Biovitrum
$0.00 /

+ (+0.00%)

BIOVF Swedish Orphan Biovitrum
$0.00 /

+ (+0.00%)

07/22/20 Barclays
Swedish Orphan Biovitrum upgraded to Overweight from Equal Weight at Barclays
06/19/20 Barclays
Barclays upgrades Swedish Orphan to Equal Weight on favorable trends
06/19/20 Barclays
Swedish Orphan upgraded to Equal Weight from Underweight at Barclays

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.